-

Reinsurance Group of America Announces Longevity Reinsurance Transaction With NN Life

AMSTERDAM--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, today announced the completion of a longevity reinsurance transaction with NN Life, the largest life insurance company in the Netherlands. The reinsurance transaction covers approximately €4 billion of underlying reserves.

“Across RGA, we pride ourselves on developing comprehensive and creative answers to our clients’ challenges while maintaining a competitive value proposition,” said Simon Wainwright, Executive Vice President, Head of EMEA, RGA. “Our recent work with NN Life was emblematic of this commitment, and we appreciated their partnership as we worked to develop a tailored solution for the needs of the Dutch market.”

The transaction was effective December 31, 2021. Additional terms of the transaction are not being disclosed.

About RGA

Reinsurance Group of America, Incorporated (RGA), a Fortune 500 company, is among the leading global providers of life reinsurance and financial solutions, with approximately $3.5 trillion of life reinsurance in force and assets of $92.2 billion as of December 31, 2021. Founded in 1973, RGA is recognized for its deep technical expertise in risk and capital management, innovative solutions, and commitment to serving its clients. With headquarters in St. Louis, Missouri, and operations around the world, RGA delivers expert solutions in individual life reinsurance, individual living benefits reinsurance, group reinsurance, health reinsurance, facultative underwriting, product development, and financial solutions. To learn more about RGA and its businesses, visit the company’s website at www.rgare.com.

Contacts

Lynn Phillips
Vice President, Corporate Communications
636-736-2351
lphillips@rgare.com

Lizzie Curry
Director, Public Relations
636-736-8521
lizzie.curry@rgare.com

Jeff Hopson
Senior Vice President, Investor Relations
636-736-2068
jhopson@rgare.com

Reinsurance Group of America, Incorporated

NYSE:RGA

Release Versions

Contacts

Lynn Phillips
Vice President, Corporate Communications
636-736-2351
lphillips@rgare.com

Lizzie Curry
Director, Public Relations
636-736-8521
lizzie.curry@rgare.com

Jeff Hopson
Senior Vice President, Investor Relations
636-736-2068
jhopson@rgare.com

More News From Reinsurance Group of America, Incorporated

Reinsurance Group of America Named to Fortune’s ‘World’s Most Admired Companies’ List

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health insurer, has been named to Fortune’s World’s Most Admired Companies list, a testament to RGA’s dedication to excellence and unwavering focus on delivering value to clients while upholding the highest standards of business operations and corporate responsibility. “We’re truly honored to be recognized by Fortune once again. It reflects the passion and commitment our employees bring...

Reinsurance Group of America Names Ryan Krueger Senior Vice President, Investor Relations

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, announced today that Ryan Krueger will join the company as Senior Vice President, Investor Relations, effective January 5, 2026. In this role, he will lead RGA’s engagement with the investor community, partnering closely with the company’s executive leadership team to articulate RGA’s strategic evolution and performance. Mr. Krueger will report to Executive Vice Presid...

New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity impacts of incretin-based therapies, including GLP-1s, approved as anti-obesity medications (AOMs) and diabetes treatments. The study examined data from four markets (US, UK, Canada, and Hong Kong) to assess how widespread adoption of AOMs could affect population health outcomes over the next two d...
Back to Newsroom